Solid Tumor Personalized TCR-T is under clinical development by Shenzhen Pregene Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Solid Tumor Personalized TCR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Solid Tumor Personalized TCR-T overview
The therapeutic candidate is under development for the treatment of solid tumor. It comprises of T-cells genetically engineered to express T cell receptors (TCR).
Shenzhen Pregene Biopharma overview
Shenzhen Pregene Biopharma a biotechnology company that operates in fusion drug and nano-antibody drug biotechnology R&D platform. The company is headquartered in Shenzhen, Guangdong, China.
For a complete picture of Solid Tumor Personalized TCR-T’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.